NASDAQ: $AMGN Promising News for Sjögren’s Syndrome Patients There is a significant glimmer of hope for individuals living with moderate-to-severe systemic Sjögren’s syndrome. Amgen has officially announced positive topline results from their Phase 3 clinical trial evaluating dazodalibep, an investigational medicine designed to address the symptoms of this challenging autoimmune condition. Understanding the Clinical Trial…